Method Article

Rapid Identification of Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum by RNA Amplification Lateral Flow Assay

693 views

DOI:

10.3791/68413

June 20th, 2025

In This Article

Summary

Here, we present a protocol demonstrating RNA amplification lateral flow assay and evaluate the efficacy for rapidly detecting Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasmaurealyticum.

Abstract

Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and Ureaplasma urealyticum (UU) are common pathogens associated with sexually transmitted diseases (STDs). NG is the causative agent of gonorrhea, which can result in various disorders of the genitourinary system, including epididymitis, prostatitis, cervicitis, and infertility. CT is a microorganism responsible for non-gonococcal urethritis and pelvic inflammatory disease. UU is associated with non-gonococcal urethritis, cervicitis, prostatitis, and infertility. Current molecular technologies for the analysis of NG, CT, and UU are often complex and time-consuming. Rapid molecular testing for these pathogens may facilitate the early diagnosis of STDs. The RNA amplification lateral flow assay (RGT) is a method that does not require nucleic acid extraction. In this process, samples are lysed to release nucleic acid fragments, which are then amplified through reverse transcription and transcription. The amplified RNA product is recognized and captured by specific probes, forming an RNA-detection probe-gold probe complex that can be immobilized on a nitrocellulose membrane via lateral flow to produce visible bands. The entire procedure takes less than 1 h. The aim of this study was to evaluate the efficacy of RGT for the rapid detection of NG, CT, and UU. A total of 1,416 samples were included. The consistency of NG, CT, and UU when analyzed by RGT compared to the polymerase chain reaction (PCR) fluorescence probing method was 99.03% (307/310), 99.38% (159/160), and 99.02% (303/306), respectively. The consistency of NG, CT, and UU when analyzed by RGT compared to gene sequencing was 99.17% (238/240), 98.95% (188/190), and 98.30% (173/176), respectively. Compared with the pathogen isolation culture method, the detection rates for NG, CT, and UU assays were 100.00% (9/9, 17/17, 8/8). The high sensitivity and specificity, ease of use, and reduced time requirements make this assay ideal for the rapid and accurate detection of NG, CT, and UU.

Introduction

Sexually transmitted infections (STIs) represent significant global public health challenges, leading to serious genital and reproductive morbidity and mortality1. Neisseria gonorrhoeae (NG) is the causative agent of gonorrhea, with approximately 87 million new cases reported annually worldwide2. This pathogen primarily induces inflammation by invading the columnar epithelium of the urogenital tract3. Chlamydia trachomatis (CT), another microorganism, is responsible for non-gonococcal urethritis and pelvic infections, accounting for around 130 million new cases each year4. Ureaplasma urealyticum (UU), the simplest and smallest self-replicating cell, readily invades damaged cervical tissue and is associated with non-gonococcal urethritis, cervicitis, prostatitis, and infertility5. All of these infections are often asymptomatic in both female and male patients, yet they can lead to severe complications if not treated promptly. Maternal infections can result in serious adverse pregnancy outcomes, including stillbirth, miscarriage, preterm birth, and direct fetal infection6. Therefore, the development of a rapid, sensitive, specific, and user-friendly method for pathogen detection is of paramount importance.

Rapid and accurate detection of pathogens is critical for effective disease diagnosis and management. Traditional culture methods, which require the isolation, culture, and identification of pathogens, have significant disadvantages, including being time-consuming and having low sensitivity. Although gene sequencing boasts a high accuracy rate, it necessitates a complex environment and equipment, making it costly and also time-consuming. Conventional molecular technologies for the analysis of NG, CT, and UU have been widely accepted; however, these methods are often complicated and time-consuming, requiring sophisticated instrumentation, trained technicians, and extended processing times. Therefore, there is a pressing need for a simple and reliable molecular diagnostic method to address the limitations of conventional approaches. The RNA amplification lateral flow assay (RGT) offers a rapid, sensitive, and specific alternative without the need for complex procedures7,8. In this method, samples are directly lysed to release nucleic acid fragments without nucleic acid extraction, and these fragments are amplified through reverse transcription and transcription. The amplified RNA product is then recognized and captured by specific probes, forming an RNA-detection probe-gold probe complex, which can be immobilized on a nitrocellulose membrane via lateral flow to create visible bands9. The entire process takes less than 1 h, making it highly suitable for emergency laboratory tests.

In this study, we recruited 1,416 samples to evaluate the use of RGT for the detection of NG, CT, and UU. Samples were analyzed using RGT, PCR fluorescence probing, gene sequencing, and pathogen isolation culture methods. The results indicated that the RGT method was accurate and consistent with conventional diagnostic methods. In conclusion, the high sensitivity and specificity, ease of use, and reduced time requirements make this assay ideal for the rapid and accurate detection of NG, CT, and UU, suggesting its promising application in the preliminary medical diagnosis of sexually transmitted diseases.

Access restricted. Please log in or start a trial to view this content.

Protocol

This study was conducted in accordance with the ethical guidelines and approval granted by the Institutional Review Board of the First People's Hospital of Foshan, Guangdong Province, China (Ethical Review Document No. LR (2025) 136). A total of 1,416 genital swab specimens (716 from female patients, 700 from male patients) were prospectively collected from individuals clinically suspected of STDs who had not undergone antibiotic therapy within the preceding 14 days (Supplementary Table 1). For each participant, paired swabs were obtained simultaneously and analyzed in parallel: one by the test method (RGT) and the other by reference method (PCR fluorescence probing, gene sequencing, and pathogen isolating culture, respectively). Inter-method agreement was quantified using Cohen's Kappa coefficient (κ), with interpretation guided by Landis and Koch's criteria.

NOTE: The assay protocol for CT and UU follows identical procedural steps to those described for NG, with modifications limited to pathogen-specific reagents. Detail reagent formulations are provided in step 2.1 (Supplementary Table 2, Supplementary Table 3, and Supplementary Table 4).

1. Sample collection

  1. Applicable specimen type: Collect genital swabs (female cervical swab, male urethral swab).
  2. Specimen collection
    1. Insert the genital swab into the male urethral orifice for 2-3 cm or into the female cervical orifice for approximately 1- 2 cm.
    2. Rotate once and hold for 10 s.
    3. Remove the swab and insert it into the collection tube containing 1 mL of normal saline.
    4. Break off and discard the tail of the swab, then tighten the tube cap.
    5. Record the collection time and conduct the test promptly.
  3. Specimen storage and transportation
    1. Transport specimens at room temperature (RT) within 4 h or at 2-8 °C with an ice pack within 24 h.
    2. Store the remaining cell pellets of processed specimens at -20 °C for 3 months or -80 °C for up to 6 months if the tests cannot be conducted in a timely manner.

2. Preparation

  1. Reagents
    1. For reagents of NG nucleic acid assay, refer to Supplementary Table 2.
    2. For reagents of CT nucleic acid assay, refer to Supplementary Table 3.
    3. For reagents of UU nucleic acid assay, refer to Supplementary Table 4.
    4. Storage: Store all reagents at temperatures ranging from -40 °C to -15 °C and the detection cards at temperatures between 2 °C and 30 °C.
      NOTE: The amplification buffer and detection solution should be equilibrated to RT before use, based on the daily detection requirements. After reaching RT, they should be stored at 4 °C and can be used for the next detection. Avoid repeated freezing and thawing. The amplification enzyme should be stored at -20 °C except during the experimental process. An increase in storage temperature can lead to a decline or loss of enzyme activity.
  2. Experimental environment requirements
    1. Conduct the experiment in four physically separated zones:
      1. Reagent preparation area: Maintain at 22 ± 1°C with positive air pressure (High-efficiency particulate air (HEPA)-filtered airflow rate ≥ 0.3 m/s). Store pre-aliquoted reagents in UV-sterilized cabinets.
      2. Sample preparation area: Perform all specimen handling in a Class II biological safety cabinet pre-treated with 70% ethanol.
      3. Amplification area: Operate thermal cyclers on anti-vibration tables.
      4. Product analysis area: Use a UV-sterilized bench (30 min exposure pre/post use).
    2. Regulate personnel and airflow in each section to prevent cross-contamination as follows:
      1. Maintain unidirectional airflow from reagent preparation to product analysis zones.
      2. Ensure negative pressure in the sample preparation area (-5 Pa relative to adjacent zones).
      3. Restrict personnel movement; decontaminate gloves with 75% ethanol before zone transitions.
      4. Install airlock doors with interlock systems (minimum 30 s delay between openings).
    3. Use zone-specific consumables (e.g., centrifuge tubes, pipette tips, etc.) and discard consumables after a single use.
    4. Maintain cleanliness and quality control:
      1. Clean benches daily with 10% sodium hypochlorite followed by 75% ethanol or distilled water.
      2. Validate consumable sterility via endotoxin testing (Limulus amebocyte lysate assay, <0.25 EU/mL).
      3. Monitor air quality weekly using settle plates (Tryptic soy agar [TSA] agar, ≤5 colony-forming unit (CFU)/plate after 4 h exposure).
  3. Personnel qualifications
    1. Possess certificates or qualifications related to PCR technology to ensure the accuracy and reliability of this experiment.

3. Lyse the cells to extract RNA

  1. Specimen processing
    1. Vortex the specimen collection tube at 2,600 times/min for 10 s to dislodge the cells from the swab head into the solution.
    2. Transfer 1 mL of the solution to a 1.5 mL microcentrifuge tube using a calibrated pipette set to 1000 µL.
    3. Centrifuge at 12,000 × g for 2 min at 25 °C.
    4. Aspirate 950 µL of the supernatant without disturbing the pellet. Resuspend the pellets in 25 µL of residual solution by pipetting up and down 10 times using a 200 µL calibrated pipette set to 50 µL.
  2. Lysis of specimen and quality control materials
    1. Pre-equilibrate cell lysis buffer and negative control at 25 °C for 15 min.
    2. Centrifuge the quality control materials at 1000 × g for 10 s at 25 °C to ensure that all powders settle at the bottom of the tube.
    3. Add 30 µL of lysis buffer to the quality control materials and 20 µL to the specimens.
    4. Incubate for 10 min at 25 °C.
      NOTE: When using the cell lysis buffer, it is essential to mix it thoroughly. Mix by pipetting 15 times (200 µL tip) and add both the particles and the liquid to the precipitate. Handle positive control in a UV-treated Class II biosafety cabinet followed by 10% sodium hypochlorite decontamination.

4. RNA isothermal amplification

  1. Pre-equilibration of the amplification buffer
    1. Thaw the amplification buffer and equilibrate at 25 °C ± 1 °C for 15 min.
  2. Control setup
    1. Include both positive and negative control in each experimental run.
  3. Tube labeling
    1. Label amplification tubes according to the number of specimens.
  4. Reaction assembly
    1. Pipette 17 µL of amplification buffer into each tube using a calibrated 20 µL pipette. Add 2 µL of the specimen or control lysate directly into the buffer droplet.
      NOTE: Ensure the lysate enters the buffer without contacting the tube wall (briefly centrifuge at 500 × g for 5 s if necessary). Immediately cap tubes to prevent aerosol contamination.
  5. Thermal activation
    1. Incubate tubes in a preheated thermal cycler under the following program:
      Step 1: 95 °C for 2 min (denaturation)
      ​Step 2: 42 °C for 2 min (primer annealing).
  6. Enzymatic amplification
    1. Add 1 µL of amplification enzyme to each tube and mix by flicking the tube 5 times followed by brief centrifugation (500 × g for 5 s). Transfer the tubes to a second preheated thermal cycler at 42 °C for 45 min immediately.
      NOTE: Use separate incubators to avoid temperature fluctuations, one set to 95 °C and the other to 42 °C. For multi-sample runs, maintain the remaining amplification tubes at 42 °C while adding the amplification enzyme to the last amplification tube.

5. Lateral flow assay

  1. Detection solution pre-equilibration
    1. Transfer the detection solution to the incubator at 42 °C for 10 min.
  2. Homogenization
    1. Vortex the detection solution at 2,600 times/min for 15 s until the color is uniform.
  3. Temperature maintenance
    1. Keep the detection solution at 25 °C ± 2 °C for ≤30 min prior to use.
  4. Reaction initiation
    1. Add 30 µL of detection solution to each amplification tube using a calibrated 20-200 µL pipette.
      NOTE: Pipette tip must contact the tube wall at a 45° angle during dispensing to prevent bubble formation.
  5. Hybridization
    1. Mix the solution by pipetting up and down 5 times and incubate in a preheated incubator at 53 °C for 10 min.
  6. Assay device preparation
    1. Remove the detection cards from foil pouches.
      NOTE: Avoid touching the sample application zone.
  7. Sample application
    1. Transfer the entire mixture to the specimen port of the detection card using a 20-200 µL pipette.
    2. Immediately place the detection card in a 42 °C incubator for 15 min.

6. Result analysis

  1. Controlled environment for readout
    1. Maintain the detection cards in a preheated incubator at 53 °C during visual interpretation to stabilize signal intensity.
  2. Visual interpretation protocol
    1. Read the test results directly by visual inspection of the bands on the detection cards within 10-20 min.
      NOTE: The result becomes invalid after 20 min.
  3. For the interpretation matrix for RGT result interpretation, refer to Supplementary Table 5.
    NOTE: Visual interpretation of the result is shown in Figure 1.

Access restricted. Please log in or start a trial to view this content.

Results

Consistency of the RGT and PCR fluorescence probing methods
A total of 310 samples were analyzed for NG, consisting of 161 females and 149 males. The positive coincidence rate was 98.78% (95%CI: 93.39%-99.97%), while the negative coincidence rate was 99.12% (95% CI: 96.87%-99.89%). The overall coincidence rate was 99.03% (95% CI: 97.20%-99.80%). The Kappa consistency value was 0.975 (95% CI: 0.947-1.003, Z = 17.171, P < 0.05) (Tab...

Access restricted. Please log in or start a trial to view this content.

Discussion

In this study, RGT was employed to detect STI pathogens, including NG, CT, and UU. When performed under stringent operational protocols, the RGT assay demonstrated strong concordance with established diagnostic methods such as PCR fluorescence probing, gene sequencing, and pathogen isolation culture techniques. The sensitivity and specificity of the RGT assay were comparable to or exceeded those of previously reported methodologies, as evidenced by comparative analyses with established benchmarks10

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest to disclose.

Acknowledgements

We thank Wuhan Zhongzhi Bio-technologies Inc. for the reagents and technical guidance offered for this study.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
10% (w/v)  sodium hypochloritePreparation in the laboratory.Preparation in the laboratory.Diluted bleach solution for decontamination and inactivation of pathogens on equipment or surfaces.
75% (v/v) ethanolAnte Food Co., Ltd (Anhui,China)http://www.antegroup.com/product_detail_cn/id/81.htmlAqueous ethanol solution used for surface disinfection
Adjustable-volume Pipette (0.5–10 μL)DLAB Scientific Co., Ltd.7010101004Single-channel micropipette for accurate handling of microliter-scale volumes.
Adjustable-volume Pipette (100–1000 μL)DLAB Scientific Co., Ltd.7010101014Single-channel pipette calibrated for large-volume liquid handling.
Adjustable-volume Pipette (10–100 μL)DLAB Scientific Co., Ltd.7010101008Single-channel pipette optimized for intermediate volumes, commonly used in molecular biology protocols.
Adjustable-volume Pipette (20–200 μL)DLAB Scientific Co., Ltd.7010101009Single-channel pipette for medium-volume transfers, suitable for precise aliquoting of reagents.
Biosafety cabinet (HF Safe-1200)HealForce Bio-Meditech Holdings Limited (Hong Kong, China)HF Safe-1200A Class II biosafety cabinet ensuring personnel, sample, and environmental protection during handling of pathogenic microorganisms or cell cultures.
Centrifuge TubesHaozhi Medical Devices Co., Ltd. (Guangzhou, China)Guangzhou Yuexiu Medical Device Filing No. 20210414For nucleic acid extraction, cell pelleting, and other laboratory procedures.
Chamydia trachomatis (CT) Nucleic Acid Assay (RNA Amplification-Lateral Flow Assay)Wuhan Zhongzhi Biotechnologies INC.(Wuhan, China)A.10.309-STD-RG-002For qualitative detection of Chamydia trachomatis nucleic acid RNA in genital and urinary tract swab samples.
CO2 IncubatorThermo Fisher Scientific(Asheville, USA) LLCSN:300504406Used for cell culture, providing a stable environment with controlled temperature (37°C), humidity, and CO2 concentration (typically 5%) to ensure optimal cell growth.
Culture Plate Corning Incorporated (Corning, USA)50 mm ´ 9 mmFor adherent cell culture and expansion.
Detection Kit for Nucleic Acid to Chamydia trachomatis (CT) (PCR-Fluorescence Probing)Fosun Diagnostics (Shanghai, China) Co., LtdChina Medical Device Registration Certificate No. 20143402234For qualitative detection of nucleic acid of Chamydia trachomatis in genital and urinary tract swab samples.
Detection Kit for Nucleic Acid to Neisseria Gonorrhoeae (NG)(PCR-Fluorescence Probing)Fosun Diagnostics (Shanghai, China) Co., LtdChina Medical Device Registration Certificate No. 20173401080For qualitative detection of nucleic acid of Neisseria gonorrhoeae in genital and urinary tract swab samples.
Detection Kit for Nucleic Acid to Ureaplasma Urealyticum (UU) (PCR-Fluorescence Probing)Fosun Diagnostics (Shanghai, China) Co., LtdChina Medical Device Registration Certificate No. 20173400536For qualitative detection of nucleic acid of Ureaplasma Urealyticum in genital and urinary tract swab samples.
DMEM mediumThermo Fisher Scientific Inc.(Waltham, USA)11965092For Chlamydia trachomatis culture.
Filter Pipette Tips (10 μL)Guangzhou Surbiopure Biotechnology Co., Ltd (Guangzhou, China)TF-10-BXLFor precise pipetting in the experiments.
Filter Pipette Tips (200 μL)Guangzhou Surbiopure Biotechnology Co., Ltd (Guangzhou, China)TF-200-BXLFor precise pipetting in the experiments.
Genital swabHaozhi Medical Devices Co., Ltd. (Guangzhou, China)Hz112Sterile cotton-tipped swabs for collecting clinical specimens from genital mucosal surfaces.
Gibco Fetal Bovine Serum (FBS)Thermo Fisher Scientific Inc. (Waltham, USA)10270106For Chlamydia trachomatis culture.
Glass slidesHaozhi Medical Devices Co., Ltd. (Guangzhou, China)Guangzhou Yuexiu Medical Device Filing No. 20210414Standard glass slides with anti-fade treatment for preparing cell smears or tissue sections, compatible with Gram staining protocols.
Goldenstar RT6 cDNA Synthesis Kit Ver2Beijing Tsingke Biotech Co., Ltd (Beijing, China)TSK302SFor the synthesis of the first strand of cDNA in the first step of the two-step RT-PCR. It contains all the reagents required for the synthesis of cDNA from RNA.
Gram Stain KitBaso Diagnostics,Inc. (Zhuhai, China)BA4012A staining kit containing crystal violet, iodine, decolorizer, and safranin for differentiating Neisseria Gonorrhoeae. 
IBM SPSS Statistics (V25.0)International Business Machines Corporation (New York, USA)Version 25.0For data analysis.
Infrared sterilizerHuaxixinrui (Qingdao) Analytical Instruments Co., Ltd.MJ-200WFor instant decontamination of inoculation loops or forceps, minimizing cross-contamination in biosafety cabinets.
Inoculation loopBKMAM Biotechnology Co., Ltd.(Hunan, China)110306002For microbial sample transfer, streaking, or inoculation.
Inverted Microscope (IX-51)Olympus Corporation (Tokyo, Japan)Asset Code of Labortory:  71807101For observing adherent cells or live-cell dynamics in culture dishes.
MALDI Biotyper automated microbial mass spectrometry systemBruker Daltonics GmbH & Co. KG (Bremen, Germany)National Medical Device Import Registration No. 20182222017A MALDI-TOF mass spectrometry-based system for rapid microbial identification via protein profiling, enabling species identification of bacteria and fungi in clinical microbiology laboratories.
McCoy cell linesPreserved in the laboratory.Preserved in the laboratory.For Chlamydia trachomatis culture.
Microplate Thermostatic Incubator Leopard70-4 (4 Plate Capacity)Leaptec Scientific Instruments (Beijing) Co., Ltd.Leopard70-4A microplate incubator accommodating up to 4 standard microplates, with a temperature range from ambient to 70°C,  used for the incubation steps.
Microscope (OLYMPUS CX43)Olympus Corporation (Tokyo, Japan)https://lifescience.evidentscientific.com.cn/zh/microscopes/upright/cx43-33/For clinical sample observation (e.g., cell morphology, stained specimens).
Mini Metal Bath MiniG-R100Leaptec Scientific Instruments (Beijing) Co., Ltd.MiniG-R100For rapid temperature regulation during the experiment, such as heating, incubating, or terminating reactions in small-volume samples.
Neisseria gonorrhoeae (NG) Nucleic Acid Assay (RNA Amplification-Lateral Flow Assay)Wuhan Zhongzhi Biotechnologies INC.(Wuhan, China)A.10.309-STD-RG-001For qualitative detection of Neisseria gonorrhoeae nucleic acid RNA in genital and urinary tract swab samples.
Nucleic Acid Extraction ReagentWuhan Zhongzhi Biotechnologies INC.(Wuhan, China)A.10.105-SC-001For the extraction, enrichment and purification of nucleic acids.
Specimen Transport MediumQIAGEN N.V. (Venlo, Netherlands)5128-1220This medium is specifically formulated for the collection, preservation, and transport of clinical specimens, ensuring the viability of Chlamydia trachomatis and Neisseria gonorrhoeae for subsequent diagnostic testing.
Thermostatic CentrifugeBeckman Coulter, Inc. (Brea, USA)SN: MRZ21L037For cell, microbial, or nucleic acid pelleting.
TM mediumShanghai Yihua Medical Science & Technology Co., Ltd (Shanghai, China)Shanghai Pu Medical Device Filing No. 20140081TM medium can be used for the isolation, cultivation and identification of Neisseria gonorrhoeae from clinical samples to assist in the diagnosis of gonorrhea.
Trypsin-EDTA (0.25%)Thermo Fisher Scientific Inc.(Waltham, USA)25200072For gentle dissociation of adherent cells during subculturing or experimental procedures.
Ureaplasma urealyticum (UU) Nucleic Acid Assay (RNA Amplification-Lateral Flow Assay)Wuhan Zhongzhi Biotechnologies INC.(Wuhan, China)A.10.309-STD-RG-003For qualitative detection of Ureaplasma Urealyticum nucleic acid RNA in genital and urinary tract swab samples.
Ureaplasma urealyticum and Mycoplasma hominis Selective Isolation Culture, Identification and Drug Sensitivity KitHebei Zhongaisheng Biotechnology Co., Ltd.(Hebei, China)Hebei Medical Device Registration No. 20152400168For the selective isolation, culture, identification, and drug sensitivity determination of Ureaplasma urealyticum and Mycoplasma hominis.
Vortex mixerXinkang Medical Instrument Co. Ltd (Jiangsu, China)XK80-ALaboratory device for homogenizing liquid samples by rapid agitation.

References

  1. Hufstetler, K., Llata, E., Miele, K., Quilter, L. A. S. Clinical updates in sexually transmitted infections, 2024. J Womens Health (Larchmt). 33 (6), 827-837 (2024).
  2. Sunkavalli, A., McClure, R., Genco, C. Molecular regulatory mechanisms drive emergent pathogenetic properties of Neisseria gonorrhoeae. Microorganisms. 10 (5), 922(2022).
  3. Quillin, S. J., Seifert, H. S. Neisseria gonorrhoeae host adaptation and pathogenesis. Nat Rev Microbiol. 16 (4), 226-240 (2018).
  4. Rowley, J., et al. Chlamydia, gonorrhoea, trichomoniasis, and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 97 (8), 548-562 (2016).
  5. Rittenschober-Boehm, J., et al. Intrauterine detection of Ureaplasma species after vaginal colonization in pregnancy and neonatal outcome. Neonatology. 121 (2), 187-194 (2024).
  6. Liu, T., et al. Analysis of Ureaplasma urealyticum, Chlamydia trachomatis, Mycoplasma genitalium and Neisseria gonorrhoeae infections among obstetrics and gynecological outpatients in southwest China: a retrospective study. BMC Infect Dis. 22 (1), 283(2022).
  7. Song, J., Zhang, L., Zeng, L., Xu, X. Visualized lateral flow assay for dual viral RNA fragment detection. Anal Chem. 95 (30), 11187-11192 (2023).
  8. Dighe, K., Moitra, P., Alafeef, M., Gunaseelan, N., Pan, D. A rapid RNA extraction-free lateral flow assay for molecular point-of-care detection of SARS-CoV-2 augmented by chemical probes. Biosens Bioelectron. 200, 113900(2002).
  9. Liu, C. C., Yeung, C. Y., Chen, P. H., Yeh, M. K., Hou, S. Y. Salmonella detection using 16S ribosomal DNA/RNA probe-gold nanoparticles and lateral flow immunoassay. Food Chem. 141 (3), 2526-2532 (2013).
  10. Pereyre, S., Caméléna, F., Hénin, N., Berçot, B., Bébéar, C. Clinical performance of four multiplex real-time PCR kits detecting urogenital and sexually transmitted pathogens. Clin Microbiol Infect. 28 (5), 733.e7-733.e13 (2022).
  11. Morris, S. R., Bristow, C. C., Wierzbicki, M. R., et al. Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. Lancet Infect Dis. 21 (5), 668-676 (2021).
  12. Pflüger, L. S., Nörz, D., Grunwald, M., et al. Analytical and clinical validation of a multiplex PCR assay for detection of Neisseria gonorrhoeae and Chlamydia trachomatis including simultaneous LGV serotyping on an automated high-throughput PCR system. Microbiol Spectr. 12 (3), e0275623(2024).
  13. Huang, Y., et al. Droplet digital PCR (ddPCR) for the detection and quantification of Ureaplasma spp. BMC Infect Dis. 21 (1), 804(2021).
  14. Ma, Y., et al. Comparison of analytical sensitivity of DNA-based and RNA-based nucleic acid amplification tests for reproductive tract infection pathogens: implications for clinical applications. Microbiol Spectr. 11 (5), e0149723(2023).
  15. Van Der Pol, B., et al. Multicenter comparison of nucleic acid amplification tests for the diagnosis of rectal and oropharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae infections. J Clin Microbiol. 60 (1), e0136321(2022).
  16. Luo, H., et al. An isothermal CRISPR-based diagnostic assay for Neisseria gonorrhoeae and Chlamydia trachomatis detection. Microbiol Spectr. 11 (6), e0046423(2023).
  17. Tu, Q., et al. Point-of-care detection of Neisseria gonorrhoeae based on RPA-CRISPR/Cas12a. AMB Express. 13 (1), 50(2023).
  18. Caruso, G., Giammanco, A., Virruso, R., Fasciana, T. Current and future trends in the laboratory diagnosis of sexually transmitted infections. Int J Environ Res Public Health. 18 (3), 1038(2021).
  19. Yang, J. L., et al. Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma. Br J Ophthalmol. 91 (3), 293-295 (2007).
  20. Luo, Z. G., Li, R. P., Wang, Y. B., Shang, X. J., Zhu, J. Y. Real-time fluorescence constant-temperature simultaneous amplification and testing of nucleic acid for detection of Mycoplasma genitalium infection in the genitourinary tract. Zhonghua Nan Ke Xue. 25 (6), Chinese 535-538 (2019).
  21. Zhang, T., et al. Light-up RNA aptamer signaling-CRISPR-Cas13a-based mix-and-read assays for profiling viable pathogenic bacteria. Biosens Bioelectron. 176, 112906(2021).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Rapid Molecular TestingSexually Transmitted DiseasesPathogen DetectionReverse TranscriptionGene Sequencing
Video Coming Soon

Related Articles